Persistent il-2 receptor signaling by il-2/cd25 fusion protein controls diabetes in nod mice by multiple mechanisms

Natasha C. Ward, Jen Bon Lui, Rosmely Hernandez, Liping Yu, Mary Struthers, Jenny Xie, Alicia Santos Savio, Connor J. Dwyer, Sunnie Hsiung, Aixin Yu, Thomas R. Malek

Research output: Contribution to journalArticlepeer-review

Abstract

Low-dose interleukin-2 (IL-2) represents a new therapeutic approach to regulate immune homeostasis to promote immune tolerance in patients with autoimmune diseases, including type 1 diabetes. We have developed a new IL-2–based biologic, an IL-2/CD25 fusion protein, with greatly improved pharmacokinetics and pharmaco-dynamics when compared with recombinant IL-2 to enhance this type of immunotherapy. In this study, we show that low-dose mouse IL-2/CD25 (mIL-2/CD25), but not an equivalent amount of IL-2, prevents the onset of diabetes in NOD mice and controls diabetes in hyperglycemic mice. mIL-2/CD25 acts not only to expand regulatory T cells (Tregs) but also to increase their activation and migration into lymphoid tissues and the pancreas. Lower incidence of diabetes is associated with increased se-rum levels of IL-10, a cytokine readily produced by activated Tregs. These effects likely act in concert to lower islet inflammation while increasing Tregs in the remain-ing inflamed islets. mIL-2/CD25 treatment is also associated with lower anti-insulin autoantibody levels in part by inhibition of T follicular helper cells. Thus, long-acting mIL-2/CD25 represents an improved IL-2 analog that persistently elevates Tregs to maintain a favorable Treg/ effector T cell ratio that limits diabetes by expansion of activated Tregs that readily migrate into lymphoid tissues and the pancreas while inhibiting autoantibodies.

Original languageEnglish (US)
Pages (from-to)2400-2413
Number of pages14
JournalDiabetes
Volume69
Issue number11
DOIs
StatePublished - Nov 2020

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'Persistent il-2 receptor signaling by il-2/cd25 fusion protein controls diabetes in nod mice by multiple mechanisms'. Together they form a unique fingerprint.

Cite this